Telimomab aritox

Telimomab aritox (pronunciation: te-li-mo-mab a-ri-tox) is a monoclonal antibody designed for the treatment of various cancer types. It is a type of biopharmaceutical that is developed in a laboratory and designed to bind to specific cells or proteins, which can stimulate the body's immune system to attack those cells.

Etymology

The name "Telimomab aritox" is derived from the standard nomenclature for monoclonal antibodies. The prefix "Teli-" is an arbitrary sequence, the infix "-momab" indicates that the antibody is of mouse origin, and the suffix "-aritox" suggests its function as a toxin.

Related Terms

Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells. They are used in cancer treatment due to their ability to attach to specific targets on the cell surface.
Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
Biopharmaceutical: A type of drug produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA, or antisense oligonucleotides), and living cells used in cell therapy.
Immune system: The body's defense against infectious organisms and other invaders. It is made up of a network of cells, tissues, and organs that work together to protect the body.